drugset
drugset / Trial / NCT04134182

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

NCT04134182 ↗

Phase 2 Unknown 8 enrolled Kidney Cancer Research Bureau
NaSingle-groupOpen-labelTreatment

Summary

The aim of this Phase 2 study is to evaluate the efficacy and safety of nivolumab, an anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody, in T1aN0M0 clear-cell RCC patients ineligible for surgical treatment.

Timeline

Start
2019-10-16
Primary completion
2021-09
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous

Indications

renal cell carcinoma